Health technology assessment : HTA
-
Health Technol Assess · Jan 2018
Review Meta AnalysisAxitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Several therapies have recently been approved for use in the NHS for pretreated advanced or metastatic renal cell carcinoma (amRCC), but there is a lack of comparative evidence to guide decisions between them. ⋯ The National Institute for Health Research Health Technology Assessment programme.